Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Up 7.85%
As of Friday, November 06, BlossomHill Therapeutics, Inc.’s BLSM share price has surged by 7.85%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: BlossomHill Therapeutics, Inc. (BLSM)
BlossomHill Therapeutics, Inc. BLSM
$13.50
1.15
9.31%
November 6, 2026 4:00:00 PM
EST
Volume: 174,332
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Commentary & Analysis
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Down 5.60%
As of Monday, November 02, BlossomHill Therapeutics, Inc.’s BLSM share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Tudor Pop
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Down 6.51%
As of Friday, October 30, BlossomHill Therapeutics, Inc.’s BLSM share price has dipped by 6.51%, which has investors questioning if this is right time to buy.Tudor Pop
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Up 6.56%
As of Monday, October 26, BlossomHill Therapeutics, Inc.’s BLSM share price has surged by 6.56%, which has investors questioning if this is right time to sell.Jenna Brashear
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Down 5.88%
As of Friday, October 23, BlossomHill Therapeutics, Inc.’s BLSM share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $429.1 | $419.8 | 37% |
|
| Shares Out (Mil) | 2.7 | 43.5 | 10% |
|
| Institutional Ownership | 48.5% | 80.9% | 22% |
|
| Float (Mil) | 17.7 | 46.7 | 27% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 173 | 281 | 43% |
|
| Price Change (52-week) |
na | 53.5% | na |
|
| Growth | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (1.8%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.898) | ($5.095) | ($3.955) | |
| Month Ago EPS | ($0.898) | ($5.095) | ($3.955) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (89.7%) | (79.5%) | (83.2%) | |
| Financials | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $301 | na |
|
| Net Income (TTM) (Mil) | ($82) | ($11) | 12% |
|
| EPS (TTM) | ($31.827) | ($0.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($71) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($62) | $2 | 19% |
|
| Long-Term Debt (Q1) (Mil) | $22 | $6 | 33% |
|
| Enterprise Value (Q1) (Mil) | $959 | $446 | 40% |
|
| Valuation | BLSM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.01 | na |
|
| P/E | na | 21.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.7% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (131.5%) | (22.2%) | 4% |
|
| ROE | 93.4% | (21.5%) | 96% |
|
| Liabilities to Assets | 33.9% | 31.5% | 25% |
|
| F-Score | 1 | 3 | na |
|
BlossomHill Therapeutics, Inc. did not pass any screens on 11/6/2026.
